Mediplus Pharma Inc. (Head Office: Shibuya-ku, Tokyo), a company engaged in the applied development of ozone for over 50 years, is pleased to announce that Kyōhei Uchida has assumed the position of President and Representative Director as of November 1, 2025.
Mediplus Pharma Inc., which has long been engaged in the applied development of ozonation®—a technology for utilizing ozone in medical settings—has been pursuing this work since its founding.
In 2008, during the process of developing a treatment for atopic dermatitis, the company obtained a patent for its unique ingredient ozonated glycerin, created using this technology.
Since then, ozonated glycerin has expanded beyond cosmetics into medical formulations used as adjunctive therapeutic agents, thanks to its antimicrobial and barrier-enhancing properties.
After joining Roughline Holdings in 2018, Mediplus Pharma’s technology was first incorporated into the flagship product Mediplus Gel in 2023.
Since then, more products featuring ozonated glycerin have been released, earning multiple beauty awards, especially in women’s media.
To maximize the functional value of ozonated glycerin, the company has recently deepened its understanding of its potential as a cosmetic ingredient through both basic research and clinical studies.
Now, in response to evolving market needs and as part of a shift into a new corporate phase, Kyōhei Uchida, who has extensive experience in the cosmetics industry, has been appointed as the new President and Representative Director.
■ Greeting
As of November 1, I have assumed the important responsibility of President and Representative Director of Mediplus Pharma Inc.
For more than thirty years in the cosmetics industry, I have been supported by many people across various fields and have learned a great deal.
I intend to make full use of this experience to bring Mediplus Pharma’s unique technologies and ingredients to even more people around the world.
I will dedicate myself to meeting the expectations and requirements of our business partners, and I humbly ask for your continued guidance and support.
■ Profile of the New President of Mediplus Pharma Inc.
Kyōhei Uchida
Joined POLA Cosmetics Co., Ltd. in 1992.
Gained experience in sales and product development at POLA Daily Cosmetics Co., Ltd., and was appointed Director in 2006.
Later served as Head of the West Japan Division in POLA’s BtoB Business Division, and in 2011 became General Manager of Public Relations and IR at POLA ORBIS Holdings Inc.
In 2012, he was seconded to Orlane Japan as President and Representative Director.
In 2017, he joined Nippi Collagen Cosmetics Co., Ltd. as Managing Director.
In 2023, he was appointed President and Representative Director of Mediplus Co., Ltd., leading to his current position.
【Company Overview】
Company Name: Mediplus Pharma Inc.
Representative: President and Representative Director Kyōhei Uchida
Head Office: 5F Ebisu MF Building, 4-6-1 Ebisu, Shibuya-ku, Tokyo
web site： https://www.mediplus-pharma.co.jp/
Business Description: Manufacture and sales of cosmetic ingredients
